Astressin TFA

[Description]:

Astressin is a potent corticotropin releasing factor (CRF) antagonist.

[Related Catalog]:

Signaling Pathways >> Others >> Others

Peptides

Research Areas >> Neurological Disease

[In Vitro]

Astressin has low affinity for the CRF binding protein and high affinity (Ki=2 nM) for the cloned pituitary receptor. Astressin shows high affinity for cloned human CRF-RA1 stably expressed in CHO cells and high potency to inhibit ACTH secretion[1].

[In Vivo]

Astressin is significantly more potent than any previously tested antagonist in reducing hypophyseal corticotropin (ACTH) secretion in stressed or adrenalectomized rats. Low doses of astressin (30 μg and 100 μg per kg) administered i.v. still produce a significant decrease in ACTH levels at 45 and 90 min, respectively[1]. Astressin significantly reverses the anxiogenic-like response induced by both social stress and ICV rat/humanCRF (r/hCRF) on the elevated plus-maze, but fails to block the effects of r/hCRF-induced locomotor activity in a familiar environment[2]. Intracerebroventricular infusion of the peptide both 30 min before and 10 min after seizures decreases damage in some hippocampal cell fields by as much as 84%, a magnitude of protection greater than reported for other CRF antagonists against other models of necrotic neuronal injury. Astressin protects even if administered only 10 min following excitotoxin exposure[3].

[Animal admin]

Rats: Rat diet is supplemented with oranges, and their water contained 0.9% NaCl. They are equipped with indwelling jugular cannulae 48 h prior to the i.v. injection of either vehicle or astressin. Astressin is first diluted in sterile, distilled, apyrogenic water, and the pH is adjusted to 7.0. Further dilutions are made in 0.04 M phosphate buffer, pH 7.4, containing 0.1% bovine serum albumin and 0.01% ascorbic acid. Blood samples are obtained immediately before treatment, as well as 15-120 min later. Decanted plasma samples are frozen until assayed for ACTH concentrations[1].

[References]

[1]. Gulyas J, et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10575-9.

[2]. Spina MG, et al. Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology. 2000 Mar;22(3):230-9.

[3]. Maecker H, et al. Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure. Brain Res. 1997 Jan 2;744(1):166-70.

[Related Small Molecules]

[ Molecular Formula ]:
C₁₆₁H₂₆₉N₄₉O₄₂

[ Molecular Weight ]:
3563.16000

[ Exact Mass ]:
3561.04000

[ PSA ]:
1489.66000

[ LogP ]:
9.58910

[ Storage condition ]:
2-8℃

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

Neurokinin B signaling in the female rat: a novel link between stress and reproduction.

Endocrinology 155(7) , 2589-601, (2014)

Acute systemic stress disrupts reproductive function by inhibiting pulsatile gonadotropin secretion. The underlying mechanism involves stress-induced suppression of the GnRH pulse generator, the funct...

Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats.

Endocrinology 155(7) , 2511-23, (2014)

Glucagon-like peptide-1 (GLP-1) and the GLP-1 receptor agonist, exendin-4 (Ex-4), potently stimulate hypothalamic-pituitary-adrenal (HPA) axis activity after either central or peripheral administratio...

Social stress and CRF-dopamine interactions in the VTA: role in long-term escalation of cocaine self-administration.

J. Neurosci. 34(19) , 6659-67, (2014)

The nature of neuroadaptations in the genesis of escalated cocaine taking remains a topic of considerable interest. Intermittent social defeat stress induces both locomotor and dopaminergic cross-sens...

Names

Biological Activity

Chemical & Physical Properties

Safety Information

Articles

Related Compounds